Search Results for "Xl880"
18:02 EDT 21st May 2013 | BioPortfolio
Original Source: A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.
Matching Channels
None
Matching News
None
Matching PubMed Articles
Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer.
Papillary renal cell cancer (RCC) constitutes approximately 10 % of renal cancers and is the commonest form after clear cell RCC, which accounts for approximately 75 % of cases. Until recently, most...
Search Whole site using Google
Loading
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
